Overview

* Incyte Q3 2025 revenue grows 20% yr/yr, beating analyst expectations

* Adjusted EPS for Q3 2025 beats consensus, reflecting strong financial performance

* Company raises 2025 revenue guidance to $4.23 - $4.32 bln, citing higher demand

Outlook

* Incyte ( INCY ) raises 2025 full-year net product revenue guidance to $4.23 - $4.32 bln

* Jakafi full-year revenue guidance raised to $3.050 - $3.075 bln

* Opzelura cream revenue guidance for 2025 remains at $630 - $670 mln

Result Drivers

* JAKAFI DEMAND - Increased patient demand for Jakafi across all indications drove revenue growth

* OPZELURA UPTAKE - Strong uptake and increased patient demand for Opzelura cream contributed to revenue growth

* NIKTIMVO LAUNCH - Successful launch of Niktimvo significantly boosted revenues

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $1.36 $1.25

Revenue bln bln (20

Analysts

)

Q3 Beat $2.26 $1.65

Adjusted (17

EPS Analysts

)

Q3 EPS $2.11

Q3 Beat $498.29 $398.79

Adjusted mln mln (11

Operatin Analysts

g Income )

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 16 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Incyte Corp ( INCY ) is $82.00, about 13.5% below its October 27 closing price of $93.08

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)